The plaintiffs in a 5-year-old lawsuit alleging securities fraud against an Ann Arbor drugmaker could get a settlement later this summer.
The class action lawsuit, filed in May 2016, alleges that Esperion Therapeutics Inc. and its CEO Tim Mayleben, made false and misleading statements to…